Strides Pharma gets USFDA nod to market HIV drug

The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news